The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
 
Matthew J. Frigault
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb; Editas Medicine; Iovance Biotherapeutics; Kite, a Gilead Company; Novartis
 
Theresa Amoloja
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Lea Micaletti Burke
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Rodica Morariu-Zamfir
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Valkal Bhatt
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Kristen Bibeau
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Research Funding - Incyte
 
Xiao Ying Tang
Employment - Kite, a Gilead Company (I)
Stock and Other Ownership Interests - Kite, a Gilead Company (I)
 
Amy Moskop
No Relationships to Disclose
 
Richard T. Maziarz
Leadership - Athersys; Century Therapeutics; Novartis; Vor Biopharma
Consulting or Advisory Role - Allovir; Artiva; CRISPR Therapeutics; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Novartis; Orca Bio
 
John F. DiPersio
Stock and Other Ownership Interests - Magenta Therapeutics; WUGEN, Inc.
Honoraria - Incyte
Consulting or Advisory Role - Amgen; Incyte; Magenta Therapeutics; Partner Therapeutics; Rivervest
Research Funding - Amphivena Therapeutics (Inst); Bigelow Aerospace (Inst); BiolineRx (Inst); Incyte (Inst); Macrogenics (Inst); Maxcyte (Inst); NeoImmuneTech (Inst); WUGEN, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - CD7 and CD2 Knockout for CART to CD7 and CDL; Combining integrin inhibitor with chemokine binders, 016131; Dextran based molecules to detect CAR-T cells; Duvelisib for treatment of cytokine release syndrome (CRS); IFNg, upregulate MHCII for relapsed AML; JAK and calcineurin inhibition, solid organ transplant; Novel WU mobilizing compounds (Inst); NT-17 to enhance CART Survival; Selection of IMPDH Mutant Stem Cells; Targeting IFNR/CSCR3 in GvHD; Triple Combination - CXCR2, VLA-4, gro-b; VLA4, gro-b; WU/SLU compounds VLA4 and CXCR2 (Inst)
Travel, Accommodations, Expenses - Amgen; Celgene; Cerus; Incyte; Novartis; Partner Therapeutics